StockNews.com initiated coverage on shares of Moleculin Biotech (NASDAQ:MBRX – Get Rating) in a report released on Friday. The firm issued a sell rating on the stock. MBRX stock opened at $1.89 on Friday. The company has a market cap of $54.01 million, a price-to-earnings ratio of -3.20 and a beta of 1.90. Moleculin Biotech […]
/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.
Analysts predict that Moleculin Biotech, Inc. (NASDAQ:MBRX – Get Rating) will report earnings of ($0.21) per share for the current quarter, Zacks reports. Zero analysts have provided estimates for Moleculin Biotech’s earnings, with the lowest EPS estimate coming in at ($0.22) and the highest estimate coming in at ($0.20). Moleculin Biotech reported earnings of ($0.20) […]
– Preliminary positive safety and efficacy data from second Phase 1 AML study supports plans to explore a Phase 1/2 of Annamycin in combination with Cytarabine.
/PRNewswire/ Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug.